Alliance for Pandemic Preparedness
March 12, 2021
ChAdOx1 nCoV-19 (AZD1222) protects against SARS-CoV-2 B.1.351 and B.1.1.7
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): animals, vaccines, variants
- [Pre-print, not peer-reviewed] An investigation of the Oxford-AstraZeneca (ChAdOx1 nCoV-1; AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in Syrian hamsters showed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to control animals.
- Histopathological evaluation showed extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. No infectious virus and minimal to no viral subgenomic RNA (sgRNA) was detected in lungs of vaccinated animals.
Fisher et al. (Mar 11, 2021). ChAdOx1 nCoV-19 (AZD1222) protects against SARS-CoV-2 B.1.351 and B.1.1.7. Pre-print downloaded Mar 12 from